SAN MATEO, Calif. and BRISTOL, Tenn., June 10, 2008 (PRIME NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) and King Pharmaceuticals, Inc. (NYSE:KG) today announced that a New Drug Application (NDA) for Remoxy(tm) has been submitted to the U.S. Food and Drug Administration (FDA). Remoxy, a unique long-acting formulation of oral oxycodone for moderate to severe chronic pain, is designed to resist common methods of prescription drug misuse and abuse.
